243 related articles for article (PubMed ID: 29019267)
21. Oridonin-loaded and GPC1-targeted gold nanoparticles for multimodal imaging and therapy in pancreatic cancer.
Qiu W; Chen R; Chen X; Zhang H; Song L; Cui W; Zhang J; Ye D; Zhang Y; Wang Z
Int J Nanomedicine; 2018; 13():6809-6827. PubMed ID: 30425490
[TBL] [Abstract][Full Text] [Related]
22. Enhanced Caspase-Mediated Abrogation of Autophagy by Temozolomide-Loaded and Panitumumab-Conjugated Poly(lactic-
Banstola A; Duwa R; Emami F; Jeong JH; Yook S
Mol Pharm; 2020 Nov; 17(11):4386-4400. PubMed ID: 33079558
[TBL] [Abstract][Full Text] [Related]
23. Multifunctional selenium nanoparticles as carriers of HSP70 siRNA to induce apoptosis of HepG2 cells.
Li Y; Lin Z; Zhao M; Xu T; Wang C; Xia H; Wang H; Zhu B
Int J Nanomedicine; 2016; 11():3065-76. PubMed ID: 27462151
[TBL] [Abstract][Full Text] [Related]
24. Galactose-modified selenium nanoparticles for targeted delivery of doxorubicin to hepatocellular carcinoma.
Xia Y; Zhong J; Zhao M; Tang Y; Han N; Hua L; Xu T; Wang C; Zhu B
Drug Deliv; 2019 Dec; 26(1):1-11. PubMed ID: 31928356
[TBL] [Abstract][Full Text] [Related]
25. Selenium nanoparticles coated with pH responsive silk fibroin complex for fingolimod release and enhanced targeting in thyroid cancer.
Zou X; Jiang Z; Li L; Huang Z
Artif Cells Nanomed Biotechnol; 2021 Dec; 49(1):83-95. PubMed ID: 33438446
[TBL] [Abstract][Full Text] [Related]
26. Selective synergistic anticancer effects of cisplatin and oridonin against human p53-mutant esophageal squamous carcinoma cells.
Yang H; Wang J; Khan S; Zhang Y; Zhu K; Zhou E; Gong M; Liu B; Kan Q; Zhang Q
Anticancer Drugs; 2022 Jan; 33(1):e444-e452. PubMed ID: 34520434
[TBL] [Abstract][Full Text] [Related]
27. The anti-tumor effect of folate-targeted liposome microbubbles loaded with oridonin as ultrasound-triggered tumor-targeted therapeutic carrier system.
Wang C; Li W; Hu B
J Drug Target; 2017 Jan; 25(1):83-91. PubMed ID: 27282800
[TBL] [Abstract][Full Text] [Related]
28. Silencing of MEF2D by siRNA Loaded Selenium Nanoparticles for Ovarian Cancer Therapy.
Wang C; Xia Y; Huo S; Shou D; Mei Q; Tang W; Li Y; Liu H; Zhou Y; Zhu B
Int J Nanomedicine; 2020; 15():9759-9770. PubMed ID: 33304100
[TBL] [Abstract][Full Text] [Related]
29. Co-delivery of docetaxel and curcumin prodrug via dual-targeted nanoparticles with synergistic antitumor activity against prostate cancer.
Yan J; Wang Y; Jia Y; Liu S; Tian C; Pan W; Liu X; Wang H
Biomed Pharmacother; 2017 Apr; 88():374-383. PubMed ID: 28122302
[TBL] [Abstract][Full Text] [Related]
30. Anti-EGFR-iRGD recombinant protein modified biomimetic nanoparticles loaded with gambogic acid to enhance targeting and antitumor ability in colorectal cancer treatment.
Zhang Z; Qian H; Huang J; Sha H; Zhang H; Yu L; Liu B; Hua D; Qian X
Int J Nanomedicine; 2018; 13():4961-4975. PubMed ID: 30214200
[TBL] [Abstract][Full Text] [Related]
31. Hyaluronic acid-modified selenium nanoparticles for enhancing the therapeutic efficacy of paclitaxel in lung cancer therapy.
Zou J; Su S; Chen Z; Liang F; Zeng Y; Cen W; Zhang X; Xia Y; Huang D
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):3456-3464. PubMed ID: 31469318
[TBL] [Abstract][Full Text] [Related]
32. Biodegradable self-assembled MPEG-PCL micelles for hydrophobic oridonin delivery in vitro.
Xue B; Wang Y; Tang X; Xie P; Wang Y; Luo F; Wu C; Qian Z
J Biomed Nanotechnol; 2012 Feb; 8(1):80-9. PubMed ID: 22515096
[TBL] [Abstract][Full Text] [Related]
33. Development of EGFR-targeted evodiamine nanoparticles for the treatment of colorectal cancer.
Li C; Cai G; Song D; Gao R; Teng P; Zhou L; Ji Q; Sui H; Cai J; Li Q; Wang Y
Biomater Sci; 2019 Aug; 7(9):3627-3639. PubMed ID: 31328737
[TBL] [Abstract][Full Text] [Related]
34. Molecular mechanisms of apoptosis and autophagy elicited by combined treatment with oridonin and cetuximab in laryngeal squamous cell carcinoma.
Cao S; Huang Y; Zhang Q; Lu F; Donkor PO; Zhu Y; Qiu F; Kang N
Apoptosis; 2019 Feb; 24(1-2):33-45. PubMed ID: 30430397
[TBL] [Abstract][Full Text] [Related]
35. Synergistic combination therapy of lung cancer using lipid-layered cisplatin and oridonin co-encapsulated nanoparticles.
Fan X; Wang T; Ji Z; Li Q; Shen H; Wang J
Biomed Pharmacother; 2021 Sep; 141():111830. PubMed ID: 34146851
[TBL] [Abstract][Full Text] [Related]
36. Anti-tumor activity of oridonin on SNU-5 subcutaneous xenograft model via regulation of c-Met pathway.
Liu H; Qian C; Shen Z
Tumour Biol; 2014 Sep; 35(9):9139-46. PubMed ID: 24916572
[TBL] [Abstract][Full Text] [Related]
37. Oridonin-induced A431 cell apoptosis partially through blockage of the Ras/Raf/ERK signal pathway.
Li D; Wu LJ; Tashiro S; Onodera S; Ikejima T
J Pharmacol Sci; 2007 Jan; 103(1):56-66. PubMed ID: 17251686
[TBL] [Abstract][Full Text] [Related]
38. Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway.
Guo Y; Shan Q; Gong Y; Lin J; Yang X; Zhou R
Cancer Biol Ther; 2012 Nov; 13(13):1244-54. PubMed ID: 22895079
[TBL] [Abstract][Full Text] [Related]
39. Highly Uniform Synthesis of Selenium Nanoparticles with EGFR Targeting and Tumor Microenvironment-Responsive Ability for Simultaneous Diagnosis and Therapy of Nasopharyngeal Carcinoma.
Huang J; Huang W; Zhang Z; Lin X; Lin H; Peng L; Chen T
ACS Appl Mater Interfaces; 2019 Mar; 11(12):11177-11193. PubMed ID: 30821437
[TBL] [Abstract][Full Text] [Related]
40. EGFR-targeted poly(ethylene glycol)-distearoylphosphatidylethanolamine micelle loaded with paclitaxel for laryngeal cancer: preparation, characterization and in vitro evaluation.
Ren H; Gao C; Zhou L; Liu M; Xie C; Lu W
Drug Deliv; 2015; 22(6):785-94. PubMed ID: 24670093
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
